Journal of the Advanced Practitioner in Oncology · 15 authors, 8 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
In the phase II DREAMM-2 study, patients with triple-class refractory multiple myeloma treated with belantamab mafodotin 2.5 mg/kg maintained core disease symptoms, health-related quality of life, and functioning on treatment. Patient-reported ocular symptoms were of finite duration, with a median time to worst severity of 45 to 64 days and median recovery time of 23.5 to 44.0 days.
This analysis from the randomized phase II DREAMM-2 study assessed patient-reported outcomes (PROs) in triple-class refractory multiple myeloma patients receiving belantamab mafodotin 2.5 mg/kg q3w. PRO instruments included the EORTC-QLQ-C30, EORTC-QLQ-MY20, OSDI, and NEI VFQ-25, administered electronically at baseline, during treatment, and at end of treatment. Disease-related PRO completion was greater than 70% at most visits, and ocular PRO completion was frequently 80% to 90% or above among 92 patients with available data. Core myeloma symptoms including fatigue and pain, overall HRQOL, and patient functioning were maintained while patients continued treatment. Ocular symptoms reached worst severity at a median of 45 to 64 days and recovered at a median of 23.5 to 44.0 days. These findings suggest belantamab mafodotin maintains patient-reported health outcomes despite ocular toxicity.
